TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8781764

Group type: EXPERIMENTAL
Intervention: C-peptide (6 pmol.kg‐1.min‐1)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Physiological saline solution
Number of subjects: 12
Study: 1345049

Group type: EXPERIMENTAL
Intervention: Ketoprofen (100 mg bid for 7 days)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 7437259

Group type: EXPERIMENTAL
Intervention: Intravenous heroin (diamorphine) 2.5 mg and 5 mg for non-dependent; 1/6, 1/3, and 1/2 of prescribed daily dose for dependent subjects
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31714798

Group type: EXPERIMENTAL
Intervention: Interpersonal Community Psychiatric Treatment (ICPT)
Number of subjects: 13
Study: 31436621

Group type: EXPERIMENTAL
Intervention: Aurix hematogel
Number of subjects: 129

Group type: COMPARATOR
Intervention: Usual and customary care
Number of subjects: 129
Study: 28800895

Group type: EXPERIMENTAL
Intervention: WeCareAdvisor™ (immediate treatment group)
Number of subjects: 57

Group type: COMPARATOR
Intervention: WeCareAdvisor™ (delayed treatment group)
Number of subjects: 57
Study: 26347052

Group type: EXPERIMENTAL
Intervention: Balance training with rhythmical cues (BRT)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Motor training (MT) without rhythmical auditory cues
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 150
Study: 22867295

Group type: EXPERIMENTAL
Intervention: Telephone counseling (unstructured/nondirective)
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Telephone counseling (unstructured/directive)
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Telephone counseling (structured/nondirective)
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Telephone counseling (structured/directive)
Number of subjects: 302

Group type: COMPARATOR
Intervention: No call/control group
Number of subjects: 302
Study: 21235696

Group type: EXPERIMENTAL
Intervention: Initial combination therapy with sitagliptin 100 mg q.d. and pioglitazone 30 mg q.d.
Number of subjects: 520

Group type: COMPARATOR
Intervention: Pioglitazone 30 mg q.d. monotherapy
Number of subjects: 520

Group type: EXPERIMENTAL
Intervention: Initial combination therapy with sitagliptin and pioglitazone
Number of subjects: 520

Group type: COMPARATOR
Intervention: Pioglitazone monotherapy
Number of subjects: 520
Study: 19491283

Group type: EXPERIMENTAL
Intervention: Cetuximab (400 mg/m² on week 1 followed by 250 mg/m² weekly)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Cetuximab
Number of subjects: 55
Study: 17218374

Group type: EXPERIMENTAL
Intervention: Controlled-release oxycodone 15 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 16676098

Group type: EXPERIMENTAL
Intervention: Zinc sulfate 100 mg/day for one month
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 14
Study: 14575232

Group type: EXPERIMENTAL
Intervention: Telmisartan 40 mg once daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Losartan 50 mg once daily
Number of subjects: 0
Study: 10474149

Group type: EXPERIMENTAL
Intervention: Macrophage colony stimulating factor (M‐CSF)
Number of subjects: 0
Study: 7740012

Group type: EXPERIMENTAL
Intervention: Classroom training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Television programming
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of classroom and television delivery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as usual (Control)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Attention control (Control)
Number of subjects: 0
Study: 2405349

Group type: EXPERIMENTAL
Intervention: Aztreonam, 150 mg/kg/day intravenously
Number of subjects: 36

Group type: COMPARATOR
Intervention: Chloramphenicol, 100 mg/kg/day orally
Number of subjects: 36
Study: 6993252

Group type: EXPERIMENTAL
Intervention: Spironolactone (100 mg) plus Althiazide (60 mg)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 29494294

Group type: EXPERIMENTAL
Intervention: SIT + BR
Number of subjects: 30

Group type: COMPARATOR
Intervention: SIT
Number of subjects: 30
Study: 27392550

Group type: EXPERIMENTAL
Intervention: Survivorship Care Plans (SCPs)
Number of subjects: 221

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 221
Study: 25343848

Group type: EXPERIMENTAL
Intervention: Mindfulness intervention (MindBabyBody program)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Care as usual (control group)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Non-randomised trial intervention
Number of subjects: 52
Study: 23485845

Group type: EXPERIMENTAL
Intervention: Thrust and nonthrust manipulation and exercise with myofascial therapy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Thrust and nonthrust manipulation and exercise without myofascial therapy
Number of subjects: 50
Study: 20806430

Group type: EXPERIMENTAL
Intervention: Probiotic group (sulfasalazine 2400 mg/d with probiotic)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sulfasalazine group (sulfasalazine 2400 mg/d)
Number of subjects: 30
Study: 18821688

Group type: EXPERIMENTAL
Intervention: Infliximab 5 mg/kg from baseline through week 96, administered every 6 weeks after a loading dose
Number of subjects: 279

Group type: COMPARATOR
Intervention: Placebo through week 24 and then infliximab 5 mg/kg from week 24 through week 96
Number of subjects: 279

Group type: COMPARATOR
Intervention: Historical control cohort from OASIS database (no prior use of anti-TNF agents)
Number of subjects: 279
Study: 15820274

Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy
Number of subjects: 62
Study: 12461760

Group type: EXPERIMENTAL
Intervention: Slow release melatonin 6 mg
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 10337851

Group type: EXPERIMENTAL
Intervention: Resistance training (RT) with chromium picolinate supplementation (17.8 micromol chromium per day, 924 microg Cr/d)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Resistance training (RT) without chromium picolinate supplementation (placebo <0.1 microg Cr/d)
Number of subjects: 32
Study: 8554944

Group type: EXPERIMENTAL
Intervention: Selegiline (four doses of 10 mg over the preceding 3 days)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 1710660

Group type: EXPERIMENTAL
Intervention: Intravenous administration of gamma globulin (IVGG) plus aspirin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 0
Study: 6939733

Group type: EXPERIMENTAL
Intervention: Self-instructional programs in nutrition
Number of subjects: 83

Group type: COMPARATOR
Intervention: Traditional lectures
Number of subjects: 83
Study: 31131679

Group type: EXPERIMENTAL
Intervention: Active SBCM (treatment)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Passive referral (control)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 61
Study: 28699628

Group type: EXPERIMENTAL
Intervention: 50% sleep restriction with advanced wake-time
Number of subjects: 18
Study: 25811951

Group type: EXPERIMENTAL
Intervention: Triclosan-coated sutures
Number of subjects: 281

Group type: COMPARATOR
Intervention: Control group (polyglactin 910 without triclosan)
Number of subjects: 281
Study: 24001006

Group type: EXPERIMENTAL
Intervention: Previous trial conflict
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sustained intertrial effects in left parietal theta power
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sustained intertrial effects in midcentral beta power
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Current trial conflict adaptation effect in midfrontal theta power
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intertrial effects
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Conflict adaptation effects in midfrontal theta power and RTs
Number of subjects: 0
Study: 21389923

Group type: EXPERIMENTAL
Intervention: Laparoscopic right hemicolectomy with extracorporeal anastomosis (LAC)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Laparoscopic right hemicolectomy with intracorporeal anastomosis (TLC)
Number of subjects: 45
Study: 19377437

Group type: EXPERIMENTAL
Intervention: Local anesthesia with premedication
Number of subjects: 60

Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 60
Study: 17362495

Group type: EXPERIMENTAL
Intervention: Immediate restoration with tapered, roughened-surface Southern implants, provisional screw-retained crowns placed within 4 hours of implant placement, and definitive crowns placed 8 weeks later
Number of subjects: 28

Group type: COMPARATOR
Intervention: Conventional two-stage restoration with tapered, roughened-surface Southern implants, provisional screw-retained crowns placed after 26 weeks, and definitive crowns placed 8 weeks later
Number of subjects: 28
Study: 15377561

Group type: EXPERIMENTAL
Intervention: Living in institutions
Number of subjects: 15403

Group type: EXPERIMENTAL
Intervention: Visual handicap
Number of subjects: 15403

Group type: EXPERIMENTAL
Intervention: Blindness
Number of subjects: 15403

Group type: EXPERIMENTAL
Intervention: Low vision
Number of subjects: 15403
Study: 10770520

Group type: COMPARATOR
Intervention: Baclofen treatment
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 9315540

Group type: EXPERIMENTAL
Intervention: Vitamin C (3 g intravenous infusion)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 8348391

Group type: EXPERIMENTAL
Intervention: Nifedipine 20 mg bid
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Diltiazem 120 mg bid
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 3528989

Group type: EXPERIMENTAL
Intervention: Relaxation training programme
Number of subjects: 33

Group type: COMPARATOR
Intervention: Information-contact condition
Number of subjects: 33

Group type: COMPARATOR
Intervention: Self-registration group
Number of subjects: 33
Study: 30923305

Group type: EXPERIMENTAL
Intervention: EVR/rTAC
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TAC Elimination
Number of subjects: 0

Group type: COMPARATOR
Intervention: TAC Control
Number of subjects: 0
Study: 28801704

Group type: EXPERIMENTAL
Intervention: Anteromedial portal (AMP) technique
Number of subjects: 88

Group type: COMPARATOR
Intervention: Transtibial (TT) technique
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Comparison of femoral tunnel orientation
Number of subjects: 88
Study: 26855045

Group type: EXPERIMENTAL
Intervention: Injectable calcium phosphate cement (Calcibon)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Local bone autograft
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Iliac crest autograft
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 45
Study: 23692637

Group type: EXPERIMENTAL
Intervention: MultiStem (400 million cells per patient)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MultiStem (1200 million cells per patient)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MultiStem
Number of subjects: 0
Study: 22710954

Group type: EXPERIMENTAL
Intervention: Preterm labor group (group I)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Gestational age‐matched control pregnants (group II)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Pregnants with labor at term (group III)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Gestational age‐matched control pregnants (group IV)
Number of subjects: 120
Study: 20106532

Group type: COMPARATOR
Intervention: Infant-directed video on
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Infant-directed video off
Number of subjects: 0
Study: 18760145

Group type: EXPERIMENTAL
Intervention: Early invasive strategy
Number of subjects: 898

Group type: EXPERIMENTAL
Intervention: N-terminal pro-brain natriuretic peptide (NT-proBNP) at 6 months
Number of subjects: 898

Group type: EXPERIMENTAL
Intervention: Male sex
Number of subjects: 898

Group type: EXPERIMENTAL
Intervention: Randomization to an early invasive strategy
Number of subjects: 898

Group type: EXPERIMENTAL
Intervention: Persistent cTnI elevation
Number of subjects: 898

Group type: EXPERIMENTAL
Intervention: NT-proBNP level at 6 months
Number of subjects: 898
Study: 15907416

Group type: EXPERIMENTAL
Intervention: Intracoronary treatment with estrogen (group 2)
Number of subjects: 30

Group type: COMPARATOR
Intervention: No intracoronary treatment (group 1)
Number of subjects: 30
Study: 12562411

Group type: EXPERIMENTAL
Intervention: Mainstream capnometry
Number of subjects: 240

Group type: COMPARATOR
Intervention: Sidestream capnometry
Number of subjects: 240
Study: 10832659

Group type: EXPERIMENTAL
Intervention: Heparin-coated circuit
Number of subjects: 20

Group type: COMPARATOR
Intervention: Uncoated circuit
Number of subjects: 20
Study: 8807689

Group type: EXPERIMENTAL
Intervention: Psychoeducational multifamily groups
Number of subjects: 68

Group type: COMPARATOR
Intervention: Episodic crisis family intervention
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Both treatment conditions
Number of subjects: 68
Study: 14621851

Group type: EXPERIMENTAL
Intervention: Polyclonal antilymphocyte globulins (ALG) for 7 days (n = 28)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Monoclonal T‐cell‐specific antibodies (OKT3) for 7 days (n = 27)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Both groups (ALG and OKT3)
Number of subjects: 55
Study: 3894437

Group type: COMPARATOR
Intervention: Fluoxetine hydrochloride
Number of subjects: 10
Study: 31542245

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (improved physical activity and healthy dietary intakes)
Number of subjects: 560

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 560

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 560
Study: 31574106

Group type: EXPERIMENTAL
Intervention: Animal-assisted therapy (AAT)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control sessions (conventional therapy)
Number of subjects: 10
Study: 27107979

Group type: EXPERIMENTAL
Intervention: Functional strength training
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Movement performance therapy
Number of subjects: 93

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 93
Study: 25348544

Group type: EXPERIMENTAL
Intervention: 1 implant in the midline (group 1)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: 2 implants in the canine areas (group 2)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 86
Study: 23183433

Group type: EXPERIMENTAL
Intervention: Treatment for tuberculosis
Number of subjects: 144
Study: 22147963

Group type: EXPERIMENTAL
Intervention: FibroSURE (FS)
Number of subjects: 2060

Group type: EXPERIMENTAL
Intervention: FibroScan (TE)
Number of subjects: 2060

Group type: EXPERIMENTAL
Intervention: Combined FibroSURE/TE
Number of subjects: 2060

Group type: EXPERIMENTAL
Intervention: Combined FS/TE in Asians
Number of subjects: 2060

Group type: EXPERIMENTAL
Intervention: Baseline FS
Number of subjects: 2060

Group type: EXPERIMENTAL
Intervention: Baseline TE
Number of subjects: 2060

Group type: EXPERIMENTAL
Intervention: Overall FS/TE agreement for F2-4
Number of subjects: 2060
Study: 19741604

Group type: EXPERIMENTAL
Intervention: MK-0493
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 30 mg sibutramine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 16289651

Group type: COMPARATOR
Intervention: Chloroquine
Number of subjects: 116

Group type: COMPARATOR
Intervention: Sulfadoxine-pyrimethamine (SP)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Mefloquine
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Mefloquine-artesunate
Number of subjects: 116
Study: 15172654

Group type: EXPERIMENTAL
Intervention: i.v. ibutilide treatment, up to 2 mg
Number of subjects: 87

Group type: COMPARATOR
Intervention: Transoesophageal atrial pacing (ATP)
Number of subjects: 87
Study: 11717611

Group type: EXPERIMENTAL
Intervention: Right Atrial Appendage Pacing (RAAP)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Interatrial Septum Pacing (IASP)
Number of subjects: 46
Study: 9142515

Group type: EXPERIMENTAL
Intervention: Normal retropharyngeal lymph nodes (RLN) size measurement
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (20 subjects)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Statistical association analysis
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Measurement of nasopharyngeal walls involvement and maximum diameter of the tumor
Number of subjects: 44
Study: 8737553

Group type: EXPERIMENTAL
Intervention: Caudal bupivacaine (0.5ml/kg body weight of 0.25% solution)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Buprenorphine (4 micrograms/ml, volume of 0.5 ml/kg body weight in normal saline)
Number of subjects: 85
Study: 3297570

Group type: EXPERIMENTAL
Intervention: Single dose of metronidazole (1.5 g) and ampicillin (3.0 g)
Number of subjects: 294

Group type: COMPARATOR
Intervention: Multiple doses of ampicillin (1 g X 3) and metronidazole (0.5 g X 3)
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: Single dose of metronidazole and ampicillin
Number of subjects: 294
Study: 1692390

Group type: EXPERIMENTAL
Intervention: IgG 7S
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: IgG 5S
Number of subjects: 64
Study: 29952805

Group type: EXPERIMENTAL
Intervention: Distortion product OAE (DPOAE) with controlled reflection-source contribution
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Distortion-source DPOAEs
Number of subjects: 212

Group type: COMPARATOR
Intervention: Reflection-source AM-SFOAEs
Number of subjects: 212

Group type: COMPARATOR
Intervention: DPOAE conditions
Number of subjects: 212
Study: 28923291

Group type: EXPERIMENTAL
Intervention: Omarigliptin 25 mg once weekly
Number of subjects: 203

Group type: COMPARATOR
Intervention: Placebo once weekly
Number of subjects: 203

Group type: COMPARATOR
Intervention: Prohibited medication (metformin)
Number of subjects: 203
Study: 25755093

Group type: EXPERIMENTAL
Intervention: Breakfast Skipping (NB) for Eaters
Number of subjects: 18

Group type: COMPARATOR
Intervention: Breakfast Eating (B) for Skippers
Number of subjects: 18
Study: 23824699

Group type: EXPERIMENTAL
Intervention: Lenalidomide
Number of subjects: 205

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 205
Study: 21565651

Group type: EXPERIMENTAL
Intervention: Web-based decision aid
Number of subjects: 264
Study: 19593171

Group type: EXPERIMENTAL
Intervention: Flumazenil (FMZ) 2 mg incremental bolus for 20 minutes for 2 consecutive days and Gabapentin (GBP) up to 1200 mg nightly for 39 days
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Flumazenil (FMZ) and Gabapentin (GBP)
Number of subjects: 60
Study: 17203620

Group type: EXPERIMENTAL
Intervention: Screening for depression in primary care
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Management strategies (training staff, consultation-liaison, collaborative care, replacement/referral)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antidepressants prescribed at effective doses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Population-level screening campaigns
Number of subjects: 0
Study: 12911364

Group type: EXPERIMENTAL
Intervention: Auscultation group
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Pressure group
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Mark group
Number of subjects: 85
Study: 11125428

Group type: EXPERIMENTAL
Intervention: ISP+ (isolated soy protein beverage providing 42 mg. of genistein and 27 mg. of daidzein daily)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: ISP- (isolated soy protein beverage providing 2.1 mg. of genistein and 1.3 mg. of daidzein daily)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control (no specific control beverage mentioned)
Number of subjects: 34
Study: 9779710

Group type: EXPERIMENTAL
Intervention: rhIL‐3 (5 microg/kg)
Number of subjects: 185

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 185
Study: 8148678

Group type: EXPERIMENTAL
Intervention: Integrated asthma care
Number of subjects: 712

Group type: COMPARATOR
Intervention: Conventional outpatient care
Number of subjects: 712
Study: 2906069

Group type: EXPERIMENTAL
Intervention: Carbidopa/levodopa
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 28700818

Group type: EXPERIMENTAL
Intervention: Doppler measurement of MCA‐PSV (MCA‐PSV Group)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Decrease in fetal Hct (fetal Hct Group)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 71
Study: 27316335

Group type: EXPERIMENTAL
Intervention: Midwifery unit
Number of subjects: 485

Group type: COMPARATOR
Intervention: Obstetric unit
Number of subjects: 485

Group type: EXPERIMENTAL
Intervention: Obstetrician involved during labor
Number of subjects: 485

Group type: EXPERIMENTAL
Intervention: Intrapartum transfer from midwifery to obstetric unit
Number of subjects: 485

Group type: EXPERIMENTAL
Intervention: Operative delivery
Number of subjects: 485

Group type: EXPERIMENTAL
Intervention: Epidural analgesia
Number of subjects: 485
Study: 24532352

Group type: EXPERIMENTAL
Intervention: Intervention (group-based counseling, 8 hours over a weekend)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control (delayed treatment with written materials only)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Intervention (biochemical confirmation)
Number of subjects: 80
Study: 23924930

Group type: EXPERIMENTAL
Intervention: Novel multi-track technique using the double-coil Inoue metal wire
Number of subjects: 62

Group type: COMPARATOR
Intervention: Conventional multi-track technique using a balloon endhole catheter and multi-track 0.035 inch stiff wire
Number of subjects: 62
Study: 19637334

Group type: EXPERIMENTAL
Intervention: 1.0 mg/kg intravenous / 1.0 mg/kg subcutaneous fontolizumab
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Fontolizumab (all groups)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 201
Study: 18838533

Group type: EXPERIMENTAL
Intervention: Low molecular weight (low‐MW) concentrated barley beta‐glucan (6 grams beta‐glucan/day)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: High molecular weight (high‐MW) concentrated barley beta‐glucan (6 grams beta‐glucan/day)
Number of subjects: 90
Study: 16649828

Group type: EXPERIMENTAL
Intervention: Atomoxetine (10 weeks treatment)
Number of subjects: 536

Group type: COMPARATOR
Intervention: Placebo (10 weeks treatment)
Number of subjects: 536